img

Global Anti-Tumor Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Anti-Tumor Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.
The global Anti-Tumor Drugs market size was US$ 94340 million in 2024 and is forecast to a readjusted size of US$ 126230 million by 2034 with a CAGR of 4.2% during the forecast period 2024-2034.
In China, Anti-tumor Drug key players include AstraZeneca, Merck & Co., Roche, Celgene, Johnson & Johnson, etc.
United States is the largest market, followed by Japan, and Europe.
In terms of sales (consumption) side, this report focuses on the sales of Anti-Tumor Drugs by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2034.
The global Anti-Tumor Drugs market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Anti-Tumor Drugs market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Roche
Novartis
Celgene
By Type
Surgical
Chemotherapy
Radiation
Targeted
Immunotherapy
By Application
Hospital Use
Clinic Use
Household
Other
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Anti-Tumor Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Anti-Tumor Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-Tumor Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Anti-Tumor Drugs Definition
1.2 Market by Type
1.2.1 Global Anti-Tumor Drugs Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Surgical
1.2.3 Chemotherapy
1.2.4 Radiation
1.2.5 Targeted
1.2.6 Immunotherapy
1.3 Market Segment by Application
1.3.1 Global Anti-Tumor Drugs Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Hospital Use
1.3.3 Clinic Use
1.3.4 Household
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Anti-Tumor Drugs Sales
2.1 Global Anti-Tumor Drugs Revenue Estimates and Forecasts 2018-2034
2.2 Global Anti-Tumor Drugs Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Anti-Tumor Drugs Revenue by Region
2.3.1 Global Anti-Tumor Drugs Revenue by Region (2018-2023)
2.3.2 Global Anti-Tumor Drugs Revenue by Region (2024-2034)
2.4 Global Anti-Tumor Drugs Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Anti-Tumor Drugs Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Anti-Tumor Drugs Sales Quantity by Region
2.6.1 Global Anti-Tumor Drugs Sales Quantity by Region (2018-2023)
2.6.2 Global Anti-Tumor Drugs Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Anti-Tumor Drugs Sales Quantity by Manufacturers
3.1.1 Global Anti-Tumor Drugs Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Anti-Tumor Drugs Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Anti-Tumor Drugs Sales in 2024
3.2 Global Anti-Tumor Drugs Revenue by Manufacturers
3.2.1 Global Anti-Tumor Drugs Revenue by Manufacturers (2018-2023)
3.2.2 Global Anti-Tumor Drugs Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Anti-Tumor Drugs Revenue in 2024
3.3 Global Anti-Tumor Drugs Sales Price by Manufacturers
3.4 Global Key Players of Anti-Tumor Drugs, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Anti-Tumor Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Anti-Tumor Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Anti-Tumor Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Anti-Tumor Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Anti-Tumor Drugs Sales Quantity by Type
4.1.1 Global Anti-Tumor Drugs Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Anti-Tumor Drugs Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Anti-Tumor Drugs Sales Quantity Market Share by Type (2018-2034)
4.2 Global Anti-Tumor Drugs Revenue by Type
4.2.1 Global Anti-Tumor Drugs Historical Revenue by Type (2018-2023)
4.2.2 Global Anti-Tumor Drugs Forecasted Revenue by Type (2024-2034)
4.2.3 Global Anti-Tumor Drugs Revenue Market Share by Type (2018-2034)
4.3 Global Anti-Tumor Drugs Price by Type
4.3.1 Global Anti-Tumor Drugs Price by Type (2018-2023)
4.3.2 Global Anti-Tumor Drugs Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Anti-Tumor Drugs Sales Quantity by Application
5.1.1 Global Anti-Tumor Drugs Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Anti-Tumor Drugs Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Anti-Tumor Drugs Sales Quantity Market Share by Application (2018-2034)
5.2 Global Anti-Tumor Drugs Revenue by Application
5.2.1 Global Anti-Tumor Drugs Historical Revenue by Application (2018-2023)
5.2.2 Global Anti-Tumor Drugs Forecasted Revenue by Application (2024-2034)
5.2.3 Global Anti-Tumor Drugs Revenue Market Share by Application (2018-2034)
5.3 Global Anti-Tumor Drugs Price by Application
5.3.1 Global Anti-Tumor Drugs Price by Application (2018-2023)
5.3.2 Global Anti-Tumor Drugs Price Forecast by Application (2024-2034)
6 North America
6.1 North America Anti-Tumor Drugs Sales by Company
6.1.1 North America Anti-Tumor Drugs Revenue by Company (2018-2023)
6.1.2 North America Anti-Tumor Drugs Sales Quantity by Company (2018-2023)
6.2 North America Anti-Tumor Drugs Market Size by Type
6.2.1 North America Anti-Tumor Drugs Sales Quantity by Type (2018-2034)
6.2.2 North America Anti-Tumor Drugs Revenue by Type (2018-2034)
6.3 North America Anti-Tumor Drugs Market Size by Application
6.3.1 North America Anti-Tumor Drugs Sales Quantity by Application (2018-2034)
6.3.2 North America Anti-Tumor Drugs Revenue by Application (2018-2034)
6.4 North America Anti-Tumor Drugs Market Size by Country
6.4.1 North America Anti-Tumor Drugs Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Anti-Tumor Drugs Revenue by Country (2018-2034)
6.4.3 North America Anti-Tumor Drugs Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Anti-Tumor Drugs Sales by Company
7.1.1 Europe Anti-Tumor Drugs Sales Quantity by Company (2018-2023)
7.1.2 Europe Anti-Tumor Drugs Revenue by Company (2018-2023)
7.2 Europe Anti-Tumor Drugs Market Size by Type
7.2.1 Europe Anti-Tumor Drugs Sales Quantity by Type (2018-2034)
7.2.2 Europe Anti-Tumor Drugs Revenue by Type (2018-2034)
7.3 Europe Anti-Tumor Drugs Market Size by Application
7.3.1 Europe Anti-Tumor Drugs Sales Quantity by Application (2018-2034)
7.3.2 Europe Anti-Tumor Drugs Revenue by Application (2018-2034)
7.4 Europe Anti-Tumor Drugs Market Size by Country
7.4.1 Europe Anti-Tumor Drugs Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Anti-Tumor Drugs Revenue by Country (2018-2034)
7.4.3 Europe Anti-Tumor Drugs Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Anti-Tumor Drugs Sales by Company
8.1.1 China Anti-Tumor Drugs Sales Quantity by Company (2018-2023)
8.1.2 China Anti-Tumor Drugs Revenue by Company (2018-2023)
8.2 China Anti-Tumor Drugs Market Size by Type
8.2.1 China Anti-Tumor Drugs Sales Quantity by Type (2018-2034)
8.2.2 China Anti-Tumor Drugs Revenue by Type (2018-2034)
8.3 China Anti-Tumor Drugs Market Size by Application
8.3.1 China Anti-Tumor Drugs Sales Quantity by Application (2018-2034)
8.3.2 China Anti-Tumor Drugs Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Anti-Tumor Drugs Sales by Company
9.1.1 APAC Anti-Tumor Drugs Sales Quantity by Company (2018-2023)
9.1.2 APAC Anti-Tumor Drugs Revenue by Company (2018-2023)
9.2 APAC Anti-Tumor Drugs Market Size by Type
9.2.1 APAC Anti-Tumor Drugs Sales Quantity by Type (2018-2034)
9.2.2 APAC Anti-Tumor Drugs Revenue by Type (2018-2034)
9.3 APAC Anti-Tumor Drugs Market Size by Application
9.3.1 APAC Anti-Tumor Drugs Sales Quantity by Application (2018-2034)
9.3.2 APAC Anti-Tumor Drugs Revenue by Application (2018-2034)
9.4 APAC Anti-Tumor Drugs Market Size by Region
9.4.1 APAC Anti-Tumor Drugs Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Anti-Tumor Drugs Revenue by Region (2018-2034)
9.4.3 APAC Anti-Tumor Drugs Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Anti-Tumor Drugs Sales by Company
10.1.1 Middle East, Africa and Latin America Anti-Tumor Drugs Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Anti-Tumor Drugs Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Anti-Tumor Drugs Market Size by Type
10.2.1 Middle East, Africa and Latin America Anti-Tumor Drugs Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Anti-Tumor Drugs Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Anti-Tumor Drugs Market Size by Application
10.3.1 Middle East, Africa and Latin America Anti-Tumor Drugs Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Anti-Tumor Drugs Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Anti-Tumor Drugs Market Size by Country
10.4.1 Middle East, Africa and Latin America Anti-Tumor Drugs Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Anti-Tumor Drugs Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Anti-Tumor Drugs Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche Overview
11.1.3 Roche Anti-Tumor Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Roche Anti-Tumor Drugs Products and Services
11.1.5 Roche Anti-Tumor Drugs SWOT Analysis
11.1.6 Roche Recent Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis Overview
11.2.3 Novartis Anti-Tumor Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Novartis Anti-Tumor Drugs Products and Services
11.2.5 Novartis Anti-Tumor Drugs SWOT Analysis
11.2.6 Novartis Recent Developments
11.3 Celgene
11.3.1 Celgene Company Information
11.3.2 Celgene Overview
11.3.3 Celgene Anti-Tumor Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Celgene Anti-Tumor Drugs Products and Services
11.3.5 Celgene Anti-Tumor Drugs SWOT Analysis
11.3.6 Celgene Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Anti-Tumor Drugs Value Chain Analysis
12.2 Anti-Tumor Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Anti-Tumor Drugs Production Mode & Process
12.4 Anti-Tumor Drugs Sales and Marketing
12.4.1 Anti-Tumor Drugs Sales Channels
12.4.2 Anti-Tumor Drugs Distributors
12.5 Anti-Tumor Drugs Customers
13 Market Dynamics
13.1 Anti-Tumor Drugs Industry Trends
13.2 Anti-Tumor Drugs Market Drivers
13.3 Anti-Tumor Drugs Market Challenges
13.4 Anti-Tumor Drugs Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Anti-Tumor Drugs Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Surgical
Table 3. Major Manufacturers of Chemotherapy
Table 4. Major Manufacturers of Radiation
Table 5. Major Manufacturers of Targeted
Table 6. Major Manufacturers of Immunotherapy
Table 7. Global Anti-Tumor Drugs Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Anti-Tumor Drugs Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 9. Global Anti-Tumor Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 10. Global Anti-Tumor Drugs Revenue Market Share by Region (2018-2023)
Table 11. Global Anti-Tumor Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 12. Global Anti-Tumor Drugs Revenue Market Share by Region (2024-2034)
Table 13. Global Anti-Tumor Drugs Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Units)
Table 14. Global Anti-Tumor Drugs Sales by Region (2018-2023) & (K Units)
Table 15. Global Anti-Tumor Drugs Sales Market Share by Region (2018-2023)
Table 16. Global Anti-Tumor Drugs Sales by Region (2024-2034) & (K Units)
Table 17. Global Anti-Tumor Drugs Sales Market Share by Region (2024-2034)
Table 18. Global Anti-Tumor Drugs Sales Quantity by Manufacturers (2018-2023) & (K Units)
Table 19. Global Anti-Tumor Drugs Sales Quantity Share by Manufacturers (2018-2023)
Table 20. Global Anti-Tumor Drugs Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 21. Global Anti-Tumor Drugs Revenue Share by Manufacturers (2018-2023)
Table 22. Global Anti-Tumor Drugs Price by Manufacturers 2018-2023 (USD/Unit)
Table 23. Global Key Players of Anti-Tumor Drugs, Industry Ranking, 2021 VS 2024
Table 24. Global Anti-Tumor Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 25. Global Anti-Tumor Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Tumor Drugs as of 2024)
Table 26. Global Key Manufacturers of Anti-Tumor Drugs, Manufacturing Base Distribution and Headquarters
Table 27. Global Key Manufacturers of Anti-Tumor Drugs, Product Offered and Application
Table 28. Global Key Manufacturers of Anti-Tumor Drugs, Date of Enter into This Industry
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Anti-Tumor Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 31. Global Anti-Tumor Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 32. Global Anti-Tumor Drugs Sales Quantity Share by Type (2018-2023)
Table 33. Global Anti-Tumor Drugs Sales Quantity Share by Type (2024-2034)
Table 34. Global Anti-Tumor Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 35. Global Anti-Tumor Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 36. Global Anti-Tumor Drugs Revenue Share by Type (2018-2023)
Table 37. Global Anti-Tumor Drugs Revenue Share by Type (2024-2034)
Table 38. Anti-Tumor Drugs Price by Type (2018-2023) & (USD/Unit)
Table 39. Global Anti-Tumor Drugs Price Forecast by Type (2024-2034) & (USD/Unit)
Table 40. Global Anti-Tumor Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 41. Global Anti-Tumor Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 42. Global Anti-Tumor Drugs Sales Quantity Share by Application (2018-2023)
Table 43. Global Anti-Tumor Drugs Sales Quantity Share by Application (2024-2034)
Table 44. Global Anti-Tumor Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 45. Global Anti-Tumor Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 46. Global Anti-Tumor Drugs Revenue Share by Application (2018-2023)
Table 47. Global Anti-Tumor Drugs Revenue Share by Application (2024-2034)
Table 48. Anti-Tumor Drugs Price by Application (2018-2023) & (USD/Unit)
Table 49. Global Anti-Tumor Drugs Price Forecast by Application (2024-2034) & (USD/Unit)
Table 50. North America Anti-Tumor Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 51. North America Anti-Tumor Drugs Sales Quantity by Company (2018-2023) & (K Units)
Table 52. North America Anti-Tumor Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 53. North America Anti-Tumor Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 54. North America Anti-Tumor Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 55. North America Anti-Tumor Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 56. North America Anti-Tumor Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 57. North America Anti-Tumor Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 58. North America Anti-Tumor Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 59. North America Anti-Tumor Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 60. North America Anti-Tumor Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 61. North America Anti-Tumor Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 62. North America Anti-Tumor Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 63. North America Anti-Tumor Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 64. North America Anti-Tumor Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 65. Europe Anti-Tumor Drugs Sales Quantity by Company (2018-2023) & (K Units)
Table 66. Europe Anti-Tumor Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 67. Europe Anti-Tumor Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 68. Europe Anti-Tumor Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 69. Europe Anti-Tumor Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 70. Europe Anti-Tumor Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 71. Europe Anti-Tumor Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 72. Europe Anti-Tumor Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 73. Europe Anti-Tumor Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 74. Europe Anti-Tumor Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 75. Europe Anti-Tumor Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 76. Europe Anti-Tumor Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 77. Europe Anti-Tumor Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 78. Europe Anti-Tumor Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 79. Europe Anti-Tumor Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 80. China Anti-Tumor Drugs Sales Quantity by Company (2018-2023) & (K Units)
Table 81. China Anti-Tumor Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 82. China Anti-Tumor Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 83. China Anti-Tumor Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 84. China Anti-Tumor Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 85. China Anti-Tumor Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 86. China Anti-Tumor Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 87. China Anti-Tumor Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 88. China Anti-Tumor Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 89. China Anti-Tumor Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 90. APAC Anti-Tumor Drugs Sales Quantity by Company (2018-2023) & (K Units)
Table 91. APAC Anti-Tumor Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 92. APAC Anti-Tumor Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 93. APAC Anti-Tumor Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 94. APAC Anti-Tumor Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 95. APAC Anti-Tumor Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 96. APAC Anti-Tumor Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 97. APAC Anti-Tumor Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 98. APAC Anti-Tumor Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 99. APAC Anti-Tumor Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 100. APAC Anti-Tumor Drugs Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 101. APAC Anti-Tumor Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 102. APAC Anti-Tumor Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 103. APAC Anti-Tumor Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 104. APAC Anti-Tumor Drugs Sales Quantity by Region (2024-2034) & (K Units)
Table 105. Middle East, Africa and Latin America Anti-Tumor Drugs Sales Quantity by Company (2018-2023) & (K Units)
Table 106. Middle East, Africa and Latin America Anti-Tumor Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 107. Middle East, Africa and Latin America Anti-Tumor Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 108. Middle East, Africa and Latin America Anti-Tumor Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 109. Middle East, Africa and Latin America Anti-Tumor Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 110. Middle East, Africa and Latin America Anti-Tumor Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 111. Middle East, Africa and Latin America Anti-Tumor Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 112. Middle East, Africa and Latin America Anti-Tumor Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 113. Middle East, Africa and Latin America Anti-Tumor Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 114. Middle East, Africa and Latin America Anti-Tumor Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Anti-Tumor Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 116. Middle East, Africa and Latin America Anti-Tumor Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 117. Middle East, Africa and Latin America Anti-Tumor Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 118. Middle East, Africa and Latin America Anti-Tumor Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 119. Middle East, Africa and Latin America Anti-Tumor Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 120. Roche Company Information
Table 121. Roche Description and Overview
Table 122. Roche Anti-Tumor Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 123. Roche Anti-Tumor Drugs Product and Services
Table 124. Roche Anti-Tumor Drugs SWOT Analysis
Table 125. Roche Recent Developments
Table 126. Novartis Company Information
Table 127. Novartis Description and Overview
Table 128. Novartis Anti-Tumor Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 129. Novartis Anti-Tumor Drugs Product and Services
Table 130. Novartis Anti-Tumor Drugs SWOT Analysis
Table 131. Novartis Recent Developments
Table 132. Celgene Company Information
Table 133. Celgene Description and Overview
Table 134. Celgene Anti-Tumor Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 135. Celgene Anti-Tumor Drugs Product and Services
Table 136. Celgene Anti-Tumor Drugs SWOT Analysis
Table 137. Celgene Recent Developments
Table 138. Key Raw Materials Lists
Table 139. Raw Materials Key Suppliers Lists
Table 140. Anti-Tumor Drugs Distributors List
Table 141. Anti-Tumor Drugs Customers List
Table 142. Anti-Tumor Drugs Market Trends
Table 143. Anti-Tumor Drugs Market Drivers
Table 144. Anti-Tumor Drugs Market Challenges
Table 145. Anti-Tumor Drugs Market Restraints
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-Tumor Drugs Product Picture
Figure 2. Global Anti-Tumor Drugs Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Anti-Tumor Drugs Market Share by Type in 2024 & 2034
Figure 4. Surgical Product Picture
Figure 5. Chemotherapy Product Picture
Figure 6. Radiation Product Picture
Figure 7. Targeted Product Picture
Figure 8. Immunotherapy Product Picture
Figure 9. Global Anti-Tumor Drugs Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 10. Global Anti-Tumor Drugs Market Share by Application in 2024 & 2034
Figure 11. Hospital Use
Figure 12. Clinic Use
Figure 13. Household
Figure 14. Other
Figure 15. Anti-Tumor Drugs Report Years Considered
Figure 16. Global Anti-Tumor Drugs Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 17. Global Anti-Tumor Drugs Revenue 2018-2034 (US$ Million)
Figure 18. Global Anti-Tumor Drugs Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 19. Global Anti-Tumor Drugs Sales Quantity 2018-2034 (K Units)
Figure 20. Global Anti-Tumor Drugs Sales Quantity Market Share by Region (2018-2023)
Figure 21. Global Anti-Tumor Drugs Sales Quantity Market Share by Region (2024-2034)
Figure 22. North America Anti-Tumor Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 23. North America Anti-Tumor Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 24. Europe Anti-Tumor Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. Europe Anti-Tumor Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 26. China Anti-Tumor Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. China Anti-Tumor Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 28. APAC Anti-Tumor Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 29. APAC Anti-Tumor Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 30. Middle East, Africa and Latin America Anti-Tumor Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 31. Middle East, Africa and Latin America Anti-Tumor Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 32. The Top 10 and Top 5 Players Market Share by Anti-Tumor Drugs Sales Quantity in 2024
Figure 33. The Top 10 and Top 5 Players Market Share by Anti-Tumor Drugs Revenue in 2024
Figure 34. Anti-Tumor Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 35. Global Anti-Tumor Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 36. Global Anti-Tumor Drugs Revenue Market Share by Type (2018-2034)
Figure 37. Global Anti-Tumor Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 38. Global Anti-Tumor Drugs Revenue Market Share by Application (2018-2034)
Figure 39. North America Anti-Tumor Drugs Revenue Market Share by Company in 2024
Figure 40. North America Anti-Tumor Drugs Sales Quantity Market Share by Company in 2024
Figure 41. North America Anti-Tumor Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 42. North America Anti-Tumor Drugs Revenue Market Share by Type (2018-2034)
Figure 43. North America Anti-Tumor Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 44. North America Anti-Tumor Drugs Revenue Market Share by Application (2018-2034)
Figure 45. North America Anti-Tumor Drugs Revenue Share by Country (2018-2034)
Figure 46. North America Anti-Tumor Drugs Sales Quantity Share by Country (2018-2034)
Figure 47. U.S. Anti-Tumor Drugs Revenue (2018-2034) & (US$ Million)
Figure 48. Canada Anti-Tumor Drugs Revenue (2018-2034) & (US$ Million)
Figure 49. Europe Anti-Tumor Drugs Sales Quantity Market Share by Company in 2024
Figure 50. Europe Anti-Tumor Drugs Revenue Market Share by Company in 2024
Figure 51. Europe Anti-Tumor Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 52. Europe Anti-Tumor Drugs Revenue Market Share by Type (2018-2034)
Figure 53. Europe Anti-Tumor Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 54. Europe Anti-Tumor Drugs Revenue Market Share by Application (2018-2034)
Figure 55. Europe Anti-Tumor Drugs Revenue Share by Country (2018-2034)
Figure 56. Europe Anti-Tumor Drugs Sales Quantity Share by Country (2018-2034)
Figure 57. Germany Anti-Tumor Drugs Revenue (2018-2034) & (US$ Million)
Figure 58. France Anti-Tumor Drugs Revenue (2018-2034) & (US$ Million)
Figure 59. U.K. Anti-Tumor Drugs Revenue (2018-2034) & (US$ Million)
Figure 60. Italy Anti-Tumor Drugs Revenue (2018-2034) & (US$ Million)
Figure 61. Russia Anti-Tumor Drugs Revenue (2018-2034) & (US$ Million)
Figure 62. China Anti-Tumor Drugs Sales Quantity Market Share by Company in 2024
Figure 63. China Anti-Tumor Drugs Revenue Market Share by Company in 2024
Figure 64. China Anti-Tumor Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 65. China Anti-Tumor Drugs Revenue Market Share by Type (2018-2034)
Figure 66. China Anti-Tumor Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 67. China Anti-Tumor Drugs Revenue Market Share by Application (2018-2034)
Figure 68. APAC Anti-Tumor Drugs Sales Quantity Market Share by Company in 2024
Figure 69. APAC Anti-Tumor Drugs Revenue Market Share by Company in 2024
Figure 70. APAC Anti-Tumor Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 71. APAC Anti-Tumor Drugs Revenue Market Share by Type (2018-2034)
Figure 72. APAC Anti-Tumor Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 73. APAC Anti-Tumor Drugs Revenue Market Share by Application (2018-2034)
Figure 74. APAC Anti-Tumor Drugs Revenue Share by Region (2018-2034)
Figure 75. APAC Anti-Tumor Drugs Sales Quantity Share by Region (2018-2034)
Figure 76. Japan Anti-Tumor Drugs Revenue (2018-2034) & (US$ Million)
Figure 77. South Korea Anti-Tumor Drugs Revenue (2018-2034) & (US$ Million)
Figure 78. China Taiwan Anti-Tumor Drugs Revenue (2018-2034) & (US$ Million)
Figure 79. Southeast Asia Anti-Tumor Drugs Revenue (2018-2034) & (US$ Million)
Figure 80. India Anti-Tumor Drugs Revenue (2018-2034) & (US$ Million)
Figure 81. Middle East, Africa and Latin America Anti-Tumor Drugs Sales Quantity Market Share by Company in 2024
Figure 82. Middle East, Africa and Latin America Anti-Tumor Drugs Revenue Market Share by Company in 2024
Figure 83. Middle East, Africa and Latin America Anti-Tumor Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 84. Middle East, Africa and Latin America Anti-Tumor Drugs Revenue Market Share by Type (2018-2034)
Figure 85. Middle East, Africa and Latin America Anti-Tumor Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 86. Middle East, Africa and Latin America Anti-Tumor Drugs Revenue Market Share by Application (2018-2034)
Figure 87. Middle East, Africa and Latin America Anti-Tumor Drugs Sales Quantity Share by Country (2018-2034)
Figure 88. Middle East, Africa and Latin America Anti-Tumor Drugs Revenue Share by Country (2018-2034)
Figure 89. Brazil Anti-Tumor Drugs Revenue (2018-2034) & (US$ Million)
Figure 90. Mexico Anti-Tumor Drugs Revenue (2018-2034) & (US$ Million)
Figure 91. Turkey Anti-Tumor Drugs Revenue (2018-2034) & (US$ Million)
Figure 92. Israel Anti-Tumor Drugs Revenue (2018-2034) & (US$ Million)
Figure 93. GCC Countries Anti-Tumor Drugs Revenue (2018-2034) & (US$ Million)
Figure 94. Anti-Tumor Drugs Value Chain
Figure 95. Anti-Tumor Drugs Production Process
Figure 96. Channels of Distribution (Direct Vs Distribution)
Figure 97. Distributors Profiles
Figure 98. Bottom-up and Top-down Approaches for This Report
Figure 99. Data Triangulation
Figure 100. Key Executives Interviewed